The FDA Advisory Committee will review Arena’s Lorqess (lorcaserin) on Sept 15, 2010 for the treatment of obesity. It’s hard to find anything positive to say about this. It looks like there’s still the marginal efficacy issue that was present before and the safety concerns, particularly regarding cardiovascular, are still there. Which means Arena has done little to increase the marginal benefit risk ratio they had before. The only question that remains unanswered is whether any of the Advisory Committee members will recommend approval.
Posts tagged ‘lorcaserin’